Go Pro
NASDAQ:QNCX

Quince Therapeutics Q2 2025 Earnings Report

Quince Therapeutics logo
$33.93 +1.82 (+5.67%)
As of 08/21/2026 04:00 PM Eastern

Quince Therapeutics EPS Results

Actual EPS
-$68.00
Consensus EPS
-$56.00
Beat/Miss
Missed by -$12.00
One Year Ago EPS
N/A

Quince Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quince Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
4:00PM ET

Quince Therapeutics Earnings Headlines

Craig Hallum Begins Coverage on Quince Therapeutics (NASDAQ:QNCX)
Quince Therapeutics (NASDAQ:QNCX) Cut to "Sell" at Wall Street Zen
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.tc pixel
Quince Therapeutics
See More Quince Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quince Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quince Therapeutics and other key companies, straight to your email.

About Quince Therapeutics

Quince Therapeutics (NASDAQ:QNCX), a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

View Quince Therapeutics Profile